Grant: Idea to Innovation
McMaster University
$125,000.00
3D Bioprinted Fibrotic Tissue Model Platform (Phase1)
EF 2024-25
Résumé
3D in vitro tissue models that complement hydrogel and animal assays are critical to understand mechanisms that result in diseases and to prospect for new drugs to treat them. 3D bioprinting is a powerful tool to create models that mimic tissue because it can deposit cells and biomolecules in well-defined spatial arrangements. We have recently developed biomaterial inks that can be 3D printed with high-fidelity, tuned for physical and biochemical properties, and maintain high cell viability. This technological advance has enabled us to implement advanced models that mimic the in situ tissue by incorporating spatial heterogeneity in the biochemical and physical properties of 3D printed microenvironments. We have focused our development on models of fibrosis, a disease with no cure that can affect multiple organs and accounts for 45% of all deaths from chronic diseases. Fibrosis presents a progressive change in tissue stiffness and composition that develops in spatially distinct regions from otherwise healthy tissue. Traditional 2D in vitro cell culture systems do not accurately model the heterogeneous tissue microenvironment. To address this, we developed a 3D printed tissue biomimetic platform that incorporates spatial heterogeneity to model the different stages of fibrosis and is compatible with primary human cells. Our market scan has found no competing technologies that provide these capabilities, and our discussions with companies and researchers studying fibrosis and developing new anti-fibrotic drugs have revealed significant interest in our biomimetic tissue platform. However, before reaching out to potential customers, we must turn our technology platform into validated products. The proposed research will: Aim 1 - Implement 3D bioprinted fibrotic tissue models in a multiwell plate format, Aim 2 - Generate data to show that the platform supports long term culture for various primary human cells, and Aim 3 - Validate the use of the fibrotic tissue models against regulatory approved anti-fibrotics. The proposed research will allow us to generate prototypes of the 3D bioprinted fibrotic tissue model platform and relevant cellular data for commercialization.
Programme
Idea to Innovation
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
598133-2024
Name nom
Moran-Mirabal, Jose JM
Department département
Chemistry & Chemical Biology
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2024
Award amount
125000
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
3D Bioprinted Fibrotic Tissue Model Platform (Phase1)
Keywords
3d bioprinting; biomimetic scaffolds; hydrogel; in vitro tissue model; lung fibrosis; lung tissue; multimaterial constructs; multiplexed assays; tissue engineering; tunable biophysical properties
Application summary
3D in vitro tissue models that complement hydrogel and animal assays are critical to understand mechanisms that result in diseases and to prospect for new drugs to treat them. 3D bioprinting is a powerful tool to create models that mimic tissue because it can deposit cells and biomolecules in well-defined spatial arrangements. We have recently developed biomaterial inks that can be 3D printed with high-fidelity, tuned for physical and biochemical properties, and maintain high cell viability. This technological advance has enabled us to implement advanced models that mimic the in situ tissue by incorporating spatial heterogeneity in the biochemical and physical properties of 3D printed microenvironments. We have focused our development on models of fibrosis, a disease with no cure that can affect multiple organs and accounts for 45% of all deaths from chronic diseases. Fibrosis presents a progressive change in tissue stiffness and composition that develops in spatially distinct regions from otherwise healthy tissue. Traditional 2D in vitro cell culture systems do not accurately model the heterogeneous tissue microenvironment. To address this, we developed a 3D printed tissue biomimetic platform that incorporates spatial heterogeneity to model the different stages of fibrosis and is compatible with primary human cells. Our market scan has found no competing technologies that provide these capabilities, and our discussions with companies and researchers studying fibrosis and developing new anti-fibrotic drugs have revealed significant interest in our biomimetic tissue platform. However, before reaching out to potential customers, we must turn our technology platform into validated products. The proposed research will: Aim 1 - Implement 3D bioprinted fibrotic tissue models in a multiwell plate format, Aim 2 - Generate data to show that the platform supports long term culture for various primary human cells, and Aim 3 - Validate the use of the fibrotic tissue models against regulatory approved anti-fibrotics. The proposed research will allow us to generate prototypes of the 3D bioprinted fibrotic tissue model platform and relevant cellular data for commercialization.